The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Gene disruption by cell-penetrating peptide-mediated delivery of Cas9 protein and guide RNA
Open accessAbstract
RNA-guided endonucleases (RGENs) derived from the CRISPR/Cas system represent an efficient tool for genome editing. RGENs consist of two components: Cas9 protein and guide RNA. Plasmid-mediated delivery of these components into cells can result in uncontrolled integration of the plasmid sequence into the host genome, and unwanted immune responses and potential safety problems that can be caused by the bacterial sequences. Furthermore, this delivery method requires transfection tools. Here we show that simple treatment with cell-penetrating peptide (CPP)-conjugated recombinant Cas9 protein and CPP-complexed guide RNAs leads to endogenous gene disruptions in human cell lines. The Cas9 protein was conjugated to CPP via a thioether bond, whereas the guide RNA was complexed with CPP, forming condensed, positively charged nanoparticles. Simultaneous and sequential treatment of human cells, including embryonic stem cells, dermal fibroblasts, HEK293T cells, HeLa cells, and embryonic carcinoma cells, with the modified Cas9 and guide RNA, leads to efficient gene disruptions with reduced off-target mutations relative to plasmid transfections, resulting in the generation of clones containing RGEN-induced mutations. Our CPP-mediated RGEN delivery process provides a plasmid-free and additional transfection reagent-free method to use this tool with reduced off-target effects. We envision that our method will facilitate RGEN-directed genome editing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“RNP electroporation exhibits higher on-target editing efficiency and lower off-target mutations than the other delivery methods”
From Off-target effects in CRISPR/Cas9 gene editing (2023) · cites this paper as Ramakrishna et al., 2014
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A powerful advantage of the CRISPR/Cas9 system is the ability to target any ∼23-bp sequence that contains a PAM motif on either strand of DNA.”
From Delivering CRISPR: a review of the challenges and approaches (2018) · cites this paper as Ramakrishna et al., 2014
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“cell-penetrating peptides (CPP), conjugated with Cas9 and complexed with gRNA enabled efficient gene silencing in human cell lines and disease models featuring fewer off-target effects when compared to plasmid transfection [153,154].”
From CRISPR-Cas: Converting A Bacterial Defence Mechanism into A State-of-the-Art Genetic Manipulation Tool (2019) · cites this paper as [153]
Experimental — accuracy not yet measuredIn the citing paper
“Ramakrishna et al. demonstrated that conjugating Cas9 and sgRNA with cell-penetrating peptides (CPPs) enhanced intracellular delivery efficiency because of the membrane-disturbed properties of CPPs.[227]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [227]
In the citing paper
“Some work with CPPs and CRISPR/Cas9 was accomplished as early as 2014 by Ramakrishna et al. (2014), who showed separate delivery of CPP–Cas9 and CPP–sgRNA to multiple human cell lines.”
From Delivering CRISPR: a review of the challenges and approaches (2018) · cites this paper as Ramakrishna et al., 2014
In the citing paper
“Ramakrishna et al. developed cell-penetrating peptide (CPP)-conjugated recombinant Cas9 protein and CPP-complexed guide RNAs for gene disruptions of CCR5 locus in human cell lines, including HEK293T, HeLa, NCCIT (a human pluripotent embryonal carcinoma cell line), human dermal fibroblasts and human embryonic stem cells.”
From Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities (2018) · cites this paper as [96]
In the citing paper
“Cell-penetrate-peptide-mediated delivery was reported to achieve higher on-to off-target activity ratio compared with plasmid-mediated delivery.53”
From CRISPR-Cas9: a new and promising player in gene therapy (2015) · cites this paper as [53]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
A Toll-like receptor recognizes bacterial DNA
Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., Matsumoto, M., Hoshino, K., Wagner, H., Takeda, K., et al. (2000) · Nature · doi:10.1038/35047123 · Cited by 6,491 · cited 3×
“responses (Hemmi et al. 2000; Wagner 2001) caused by bacterial sequences, and safety problems if the antibiotic-resistance gene is taken up by pathogenic bacteria.”
BackgroundInfluentialDNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
Wang, H., Yang, H., Shivalila, C. S., Dawlaty, M. M., Cheng, A. W., Zhang, F., & Jaenisch, R. (2013) · Cell · doi:10.1016/j.cell.2013.04.025 · Cited by 3,495
Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity
Ran, F. A., Hsu, P. D., Lin, C.-Y., Gootenberg, J. S., Konermann, S., Trevino, A. E., Scott, D. A., Inoue, A., Matoba, S., Zhang, Y., et al. (2013) · Cell · doi:10.1016/j.cell.2013.08.021 · Cited by 3,299
High-Frequency off-Target Mutagenesis Induced by CRISPR-Cas Nucleases in Human Cells
Fu, Y., Foden, J. A., Khayter, C., Maeder, M. L., Reyon, D., Joung, J. K., & Sander, J. D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2623 · Cited by 3,292
Efficient genome editing in zebrafish using a CRISPR-Cas system
Hwang, W. Y., Fu, Y., Reyon, D., Maeder, M. L., Tsai, S. Q., Sander, J. D., Peterson, R. T., Yeh, J.-R. J., & Joung, J. K. (2013) · Nature Biotechnology · doi:10.1038/nbt.2501 · Cited by 2,937
CRISPR/Cas, the Immune System of Bacteria and Archaea
Horvath, P., & Barrangou, R. (2010) · Science · doi:10.1126/science.1179555 · Cited by 2,471
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–400 of 653
Odahara, M., Watanabe, K., Kawasaki, R., Tsuchiya, K., Tateishi, A., Motoda, Y., Kigawa, T., Kodama, Y., & Numata, K. (2021) · ACS Applied Nano Materials · doi:10.1021/acsanm.1c00695 · Cited by 29
Bhattacharjee, R., Jana, A., Nandi, A., Sinha, A., Bhattacharjee, A., Mitra, S., Kar, S., Dey, A., Singh, S. K., Varma, R. S., et al. (2022) · Materials & Design · doi:10.1016/j.matdes.2022.111415 · Cited by 29
Genome editing in maize and sorghum: A comprehensive review of CRISPR/Cas9 and emerging technologies
Namata, M. J., Xu, J., Habyarimana, E., Palakolanu, S. R., Wang, L., & Li, J. (2025) · The Plant Genome · doi:10.1002/tpg2.70038 · Cited by 36
Que, Q., Chilton, M.-D., Elumalai Sivamani, A., Zhong, H., Dong, S., & Shi, L. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8778-8_1 · Cited by 29
A CRISPR/Cas9 based polymeric nanoparticles to treat/inhibit microbial infections
Verma, R., Sahu, R., Singh, D. D., & Egbo, T. E. (2019) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2019.04.007 · Cited by 29
Shi, Y.-Y., Fan, G., Tan, R., Li, S., Sun, H.-B., Li, R., Yang, M., Gao, S., Liu, M., & Dai, M.-Y. (2024) · Cell Death & Disease · doi:10.1038/s41419-024-07073-y · Cited by 28
Peeling back the layers of immunogenicity in Cas9-based genomic medicine
Stigzelius, V., Cavallo, A. L., Chandode, R. K., & Nitsch, R. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.06.045 · Cited by 30
Key considerations in designing CRISPR/Cas9-carrying nanoparticles for therapeutic genome editing
Xu, Y., Liu, R., & Dai, Z. (2020) · Nanoscale · doi:10.1039/d0nr05452f · Cited by 27
Hasanzadeh, A., Radmanesh, F., Hosseini, E. S., Hashemzadeh, I., Kiani, J., Nourizadeh, H., Naseri, M., Fatahi, Y., Chegini, F., Madjd, Z., et al. (2021) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.1c00309 · Cited by 28
The evolution of CRISPR/Cas9 and their cousins: hope or hype?
Bhushan, K., Chattopadhyay, A., & Pratap, D. (2018) · Biotechnology Letters · doi:10.1007/s10529-018-2506-7 · Cited by 27
In vivo methods for acute modulation of gene expression in the central nervous system
Cwetsch, A. W., Pinto, B., Savardi, A., & Cancedda, L. (2018) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.04.008 · Cited by 26
Thach, T. T., Bae, D. H., Kim, N. H., Kang, E. S., Lee, B. S., Han, K., Kwak, M., Choi, H., Nam, J., Bae, T., et al. (2019) · Small · doi:10.1002/smll.201903172 · Cited by 26
Harnessing the Prokaryotic Adaptive Immune System as a Eukaryotic Antiviral Defense
Price, A. A., Grakoui, A., & Weiss, D. S. (2016) · Trends in Microbiology · doi:10.1016/j.tim.2016.01.005 · Cited by 26
Application of CRISPR-Cas9-Mediated Genome Editing for the Treatment of Myotonic Dystrophy Type 1
Marsh, S., Hanson, B., Wood, M. J. A., Varela, M. A., & Roberts, T. C. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.10.005 · Cited by 29
Exploring CRISPR-Cas: The transformative impact of gene editing in molecular biology
Pandey, V. P., Sharma, S., & Pokharel, Y. R. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102717 · Cited by 29
Cottle, R. N., Lee, C. M., Archer, D. R., & Bao, G. (2015) · Scientific Reports · doi:10.1038/srep16031 · Cited by 26
Bae, T., Hur, J. W., Kim, D., & Hur, J. K. (2019) · Genes & Genomics · doi:10.1007/s13258-019-00830-w · Cited by 26
CRISPR/Cas therapeutic strategies for autosomal dominant disorders
Caruso, S. M., Quinn, P. M. J., da Costa, B. L., & Tsang, S. H. (2022) · Journal of Clinical Investigation · doi:10.1172/jci158287 · Cited by 26
CRISPR/Cas9 in the era of nanomedicine and synthetic biology
Schmidt, T. J. N., Berarducci, B., Konstantinidou, S., & Raffa, V. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103375 · Cited by 26
Dharmalingam, P., Rachamalla, H. K., Lohchania, B., Bandlamudi, B. P., Thangavel, S., Mohankumar, K. M., Banerjee, R., Chaudhuri, A., Voshavar, C., & Marepally, S. K. (2017) · ACS Omega · doi:10.1021/acsomega.7b00935 · Cited by 25
Cas9HF1 enhanced specificity in Ustilago maydis
Zuo, W., Depotter, J. R. L., & Doehlemann, G. (2020) · Fungal Biology · doi:10.1016/j.funbio.2020.02.006 · Cited by 20
Lipid and polymer mediated CRISPR/Cas9 gene editing
Gong, Y., Tian, S., Yang, X., & Zhang, S. (2020) · Journal of Materials Chemistry B · doi:10.1039/d0tb00207k · Cited by 25
Active Delivery of CRISPR System Using Targetable or Controllable Nanocarriers
Lyu, Y., Yang, C., Lyu, X., & Pu, K. (2021) · Small · doi:10.1002/smll.202005222 · Cited by 25
Ramakrishnan, M., Kaul, R., Sharma, A., Ahmad, Z., Vijayakanth, V., Keerthana, K., Gao, Z., Zhou, M., & Wei, Q. (2025) · Plant Cell & Environment · doi:10.1111/pce.70176 · Cited by 26
A review of genetic engineering biotechnologies for enhanced chronic wound healing
Sessions, J. W., Armstrong, D. G., Hope, S. I., & Jensen, B. D. (2016) · Experimental Dermatology · doi:10.1111/exd.13185 · Cited by 25
Liu, J., & Shui, S. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.11.014 · Cited by 24
Modeling Neuropsychiatric and Neurodegenerative Diseases With Induced Pluripotent Stem Cells
LaMarca, E. A., Powell, S. K., Akbarian, S., & Brennand, K. (2018) · Frontiers in Pediatrics · doi:10.3389/fped.2018.00082 · Cited by 29
CRISPR/Cas9: A new tool for the study and control of helminth parasites
Du, X., McManus, D. P., French, J. D., Jones, M. K., & You, H. (2020) · BioEssays · doi:10.1002/bies.202000185 · Cited by 24
Salekdeh, P. R., Ma’mani, L., Tavakkoly‐Bazzaz, J., Mousavi, H., Modarressi, M. H., & Salekdeh, G. H. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-00838-z · Cited by 26
Rh D blood group conversion using transcription activator-like effector nucleases
Kim, Y., Kim, H. O., Baek, E. J., Kurita, R., Cha, H., Nakamura, Y., & Kim, S. (2015) · Nature Communications · doi:10.1038/ncomms8451 · Cited by 25
Self-citationTan, X., Bruchez, M. P., & Armitage, B. A. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00495 · Cited by 25
CRISPR-Cas9: A multifaceted therapeutic strategy for cancer treatment
Kaushik, I., Ramachandran, S., & Srivastava, S. (2019) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2019.04.018 · Cited by 25
Tahir, T., Ali, Q., Rashid, M., & Malik, A. (2020) · Biological and Clinical Sciences Research Journal · doi:10.54112/bcsrj.v2020i1.17 · Cited by 23
Singh, H., Janiyani, K., Gangawane, A., Pandya, S. R., & Jasani, S. (2024) · Discover Applied Sciences · doi:10.1007/s42452-024-06405-z · Cited by 26
Genome Editing in Neurosciences
Jaenisch, R., Gage, F. H., & Zhang, F. (2017) · Research and perspectives in neurosciences · doi:10.1007/978-3-319-60192-2 · Cited by 23
Therapeutic application of the CRISPR system: current issues and new prospects
Lee, M., & Kim, S. (2019) · Human Genetics · doi:10.1007/s00439-019-02028-2 · Cited by 23
CRISPR/Cas System: An Introduction
Munawar, N., & Ahmad, A. (2021) · Springer eBooks · doi:10.1007/978-981-15-7142-8_1 · Cited by 26
Lisjak, M., Caneva, A. D., Marais, T., Barbon, E., Biferi, M. G., Porro, F., Barzel, A., Zentilin, L., Kay, M. A., Mingozzi, F., et al. (2022) · Frontiers in Genome Editing · doi:10.3389/fgeed.2022.785698 · Cited by 24
Type II CRISPR/Cas9 approach in the oncological therapy
Biagioni, A., Chillà, A., Andreucci, E., Laurenzana, A., Margheri, F., Peppicelli, S., Rosso, M. D., & Fibbi, G. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0550-0 · Cited by 23
The application of CRISPR-Cas9 genome editing tool in cancer immunotherapy
Wu, H., & Cao, C. (2018) · Briefings in Functional Genomics · doi:10.1093/bfgp/ely011 · Cited by 22
CRISPR-sub: Analysis of DNA substitution mutations caused by CRISPR-Cas9 in human cells
Hwang, G., Yu, J., Yang, S., Son, W. J., Lim, K., Kim, H. S., Kim, J., & Bae, S. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.06.026 · Cited by 23
Self-citationRevisiting gene delivery to the brain: silencing and editing
Conniot, J., Talebian, S., Simões, S. M. N., Ferreira, L., & Conde, J. (2020) · Biomaterials Science · doi:10.1039/d0bm01278e · Cited by 25
Overview of CRISPR–Cas9 BiologyPreprint
Ratner, H. K., Sampson, T. R., & Weiss, D. S. (2016) · Cold Spring Harbor Protocols · doi:10.1101/pdb.top088849 · Cited by 28
Garrigues, S., Peng, M., Kun, R. S., & de Vries, R. P. (2023) · mBio · doi:10.1128/mbio.00668-23 · Cited by 22
A highly efficient cell penetrating peptide pVEC-mediated protein delivery system into microalgae
Kang, S., Suresh, A., & Kim, Y. (2017) · Algal Research · doi:10.1016/j.algal.2017.04.022 · Cited by 22
Heeren, J. J. F. (2022) · BioTech · doi:10.3390/biotech11030025 · Cited by 23
Generation of genetically modified mice using CRISPR/Cas9 and haploid embryonic stem cell systems.
Jin, L., & Li, J. (2016) · Europe PMC (PubMed Central) · doi:10.13918/j.issn.2095-8137.2016.4.205 · Cited by 22
CRISPR‐Cas9: A cornerstone for the evolution of precision medicine
Razzouk, S. (2018) · Annals of Human Genetics · doi:10.1111/ahg.12271 · Cited by 22
Liu, B., He, X., Zhuo, R., & Cheng, S. (2018) · Nanoscale · doi:10.1039/c8nr07321j · Cited by 22
Dowaidar, M. (2024) · Cellular Signalling · doi:10.1016/j.cellsig.2024.111116 · Cited by 21
RetractedGenome Editing in Penicillium chrysogenum Using Cas9 Ribonucleoprotein Particles
Pohl, C., Mózsik, L., Driessen, A. J. M., Bovenberg, R. A. L., & Nygård, Y. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7795-6_12 · Cited by 21
Systems of Delivery of CRISPR/Cas9 Ribonucleoprotein Complexes for Genome Editing
Амирханов, Р. Н., & Stepanov, G. A. (2019) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162019060025 · Cited by 21
Ikeda, M., Taniguchi‐Ikeda, M., Kato, T., Shinkai, Y., Tanaka, S., Hagiwara, H., Sasaki, N., Masaki, T., Matsumura, K., Sonoo, M., et al. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.05.024 · Cited by 20
Versatile modification of the CRISPR/Cas9 ribonucleoprotein system to facilitate in vivo application
Sun, B., Chen, H., & Gao, X. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.08.007 · Cited by 20
Knock-In of a Large Reporter Gene via the High-Throughput Microinjection of the CRISPR/Cas9 System
Chen, S., Jiao, Y., Pan, F., Guan, Z., Cheng, S. H., & Sun, D. B. (2022) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2022.3149530 · Cited by 21
Adherens junctions organize size-selective proteolytic hotspots critical for Notch signalling
Kwak, M., Southard, K. M., Kim, W. R., Lin, A., Kim, N. H., Gopalappa, R., Lee, H. J., An, M., Choi, S. H., Jung, Y., et al. (2022) · Nature Cell Biology · doi:10.1038/s41556-022-01031-6 · Cited by 21
Self-citationGan, S. Y., & Maggs, C. A. (2017) · European Journal of Phycology · doi:10.1080/09670262.2017.1358827 · Cited by 20
Harnessing CRISPR/Cas 9 System for manipulation of DNA virus genome
Ebrahimi, S., Teimoori, A., Khanbabaei, H., & Tabasi, M. (2018) · Reviews in Medical Virology · doi:10.1002/rmv.2009 · Cited by 20
Lindel, F., Dodt, C., Weidner, N., Noll, M., Bergemann, F., Behrendt, R., Fischer, S., Dietrich, J., Cartellieri, M., Hamann, M. V., et al. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.10.006 · Cited by 22
Prospect of cell penetrating peptides in stem cell tracking
Zhang, X., Lei, T., & Du, H. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02522-3 · Cited by 20
Rhie, B., Antao, A. M., Karapurkar, J. K., Kim, M.-S., Jo, W.-J., Ramakrishna, S., & Kim, K.-S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115584 · Cited by 20
Self-citationUSP48 Governs Cell Cycle Progression by Regulating the Protein Level of Aurora B
Antao, A. M., Kaushal, K., Das, S., Singh, V., Suresh, B., Kim, K.-S., & Ramakrishna, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168508 · Cited by 19
Self-citationMiwa, A., & Kamiya, K. (2022) · ACS Synthetic Biology · doi:10.1021/acssynbio.2c00413 · Cited by 19
Engineering cell-based therapies to interface robustly with host physiology
Schwarz, K. A., & Leonard, J. N. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.05.019 · Cited by 20
Im, J., Das, S., Jeong, D., Kim, C., Lim, H., Kim, K. H., & Chung, S. K. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.06.030 · Cited by 19
Tálas, A., Kulcsár, P. I., Weinhardt, N., Borsy, A., Tóth, E., Szebényi, K., Krausz, S. L., Huszár, K., Vida, I., Sturm, Á., et al. (2017) · DNA Research · doi:10.1093/dnares/dsx029 · Cited by 19
Ubiquitin-Specific Protease 29 Regulates Cdc25A-Mediated Tumorigenesis
Chandrasekaran, A. P., Woo, S. H., Sarodaya, N., Rhie, B., Tyagi, A., Das, S., Suresh, B., Ko, N. R., Oh, S. J., Kim, K.-S., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115766 · Cited by 19
Self-citationOrganic Mitoprobes based on Fluorogens with Aggregation‐Induced Emission
Cai, X., Hu, F., Feng, G., Kwok, R. T. K., Liu, B., & Tang, B. Z. (2018) · Israel Journal of Chemistry · doi:10.1002/ijch.201800031 · Cited by 19
Optimization of CRISPR–Cas system for clinical cancer therapy
Meng, X. L., Wu, T., Lou, Q., Niu, K., Jiang, L., Xiao, Q., Xu, T., & Zhang, L. (2022) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10474 · Cited by 18
Genome engineering in insects: focus on the CRISPR/Cas9 system
Hillary, V. E., Ceasar, S. A., & Savarimuthu Ignacimuthu, S. J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818140-9.00018-0 · Cited by 17
E3 Ubiquitin Ligase APC/CCdh1 Regulation of Phenylalanine Hydroxylase Stability and Function
Tyagi, A., Sarodaya, N., Kaushal, K., Chandrasekaran, A. P., Antao, A. M., Suresh, B., Rhie, B., Kim, K. S., & Ramakrishna, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239076 · Cited by 20
Self-citationCRISPR/Cas9–Mediated Gene Knockout and Knockin Human iPSCs
Petazzi, P., Menéndez, P. R., & Sevilla, A. (2020) · Methods in molecular biology · doi:10.1007/7651_2020_337 · Cited by 16
Won, E.-J., Park, H., Yoon, T., & Cho, Y. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14010137 · Cited by 17
CRISPR-based tools for plant genome engineering
Silva, N. V. E., & Patron, N. J. (2017) · Emerging Topics in Life Sciences · doi:10.1042/etls20170011 · Cited by 17
Park, M.-J., Moon, S., Lee, E., Kim, E., Baek, J.-A., Kim, S. Y., Jung, K. A., Lee, S., Choi, J. W., Kim, D.-S., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01526 · Cited by 17
Self-citationPerfecting Targeting in CRISPR
Zhang, H., Li, T., Sun, Y., & Yang, H. (2021) · Annual Review of Genetics · doi:10.1146/annurev-genet-071719-030438 · Cited by 18
Oakes, B. L., Xia, D. F., Rowland, E. F., Xu, D. J., Ankoudinova, I., Borchardt, J. S., Zhang, L., Li, P. W. F., Miller, J. C., Rebar, E. J., et al. (2016) · Nature Communications · doi:10.1038/ncomms10194 · Cited by 16
Genome Engineering in Human Cells
Song, M., Kim, Y., Kim, J., & Kim, S. (2014) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-801185-0.00005-2 · Cited by 18
A Simple Cloning-free Method to Efficiently Induce Gene Expression Using CRISPR/Cas9
Fang, L., Hung, S. S. C., Yek, J., Wazan, L. E., Nguyen, T., Khan, S., Lim, S. Y., Hewitt, A. W., & Wong, R. C. B. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.11.008 · Cited by 18
Li, J., Tuma, J., Han, H., Kim, H., Wilson, R. C., Lee, H. Y., & Murthy, N. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202102118 · Cited by 16
Self-citationBaig, M. M. F. A., Chien, W. T., & Chair, S. Y. (2025) · Biomaterials Science · doi:10.1039/d5bm00711a · Cited by 19
Tailoring non-viral delivery vehicles for transporting genome-editing tools
Sun, W., & Gu, Z. (2016) · Science China Materials · doi:10.1007/s40843-016-5154-4 · Cited by 16
Lee, J. H., Kang, Y. K., Oh, E., Jeong, J., Im, S. H., Kim, D. K., Lee, H., Kim, S., Jung, K., & Chung, H. J. (2021) · Chemistry of Materials · doi:10.1021/acs.chemmater.1c02844 · Cited by 16
CRISPR/Cas9 as a Mutagenic Factor
Shumega, A. R., Pavlov, Y. I., Chirinskaite, A. V., Rubel, A. A., Inge-Vechtomov, S. G., & Stepchenkova, E. I. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25020823 · Cited by 18
DMSO increases efficiency of genome editing at two non-coding loci
Stratigopoulos, G., Rosa, M. C. D., LeDuc, C. A., Leibel, R. L., & Doege, C. A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0198637 · Cited by 15
Valproic Acid Significantly Improves CRISPR/Cas9-Mediated Gene Editing
Park, H., Shin, J., Choi, H. G., Cho, B., & Kim, J. (2020) · Cells · doi:10.3390/cells9061447 · Cited by 16
Efficient CRISPR/Cas9-mediated gene disruption in the tetraploid protist Giardia intestinalis
Horáčková, V., Voleman, L., Hagen, K. D., Petrů, M., Vinopalová, M., Weisz, F., Janowicz, N. E., Marková, L., Motyčková, A., Najdrová, V., et al. (2022) · Open Biology · doi:10.1098/rsob.210361 · Cited by 18
Shin, J., Lee, N., Song, Y., Park, J., Kang, T. J., Kim, S. C., Lee, G. M., & Byung-Kwan, C. (2015) · Biotechnology and Bioprocess Engineering · doi:10.1007/s12257-015-0233-7 · Cited by 16
Engineering CRISPR-Cas9 RNA–Protein Complexes for Improved Function and Delivery
Rouet, R., de Oñate, L., Li, J., Murthy, N., & Wilson, R. C. (2018) · The CRISPR Journal · doi:10.1089/crispr.2018.0037 · Cited by 16
CRISPR delivery systems for organ-specific targeting: Advances and challenges
Du, J., Wu, Q., Liu, C., Wang, N., & Gong, C. (2025) · Precision medicine and engineering. · doi:10.1016/j.preme.2025.100048 · Cited by 20
Dizaji, N. M., Lin, Y., Bein, T., Wagner, E., Wuttke, S., Lächelt, U., & Engelke, H. (2022) · Chemistry of Materials · doi:10.1021/acs.chemmater.2c01736 · Cited by 15
Delivery challenges for CRISPR—Cas9 genome editing for Duchenne muscular dystrophy
Padmaswari, M. H., Agrawal, S., Jia, M. S., Ivy, A., Maxenberger, D. A., Burcham, L. A., & Nelson, C. E. (2023) · Biophysics Reviews · doi:10.1063/5.0131452 · Cited by 18
Delivering the Goods for Genome Engineering and Editing
Skipper, K. A., & Mikkelsen, J. G. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.063 · Cited by 16
Cell-penetrating peptides for medical theranostics and targeted drug delivery
Huang, Y., & Lee, H. (2017) · Elsevier eBooks · doi:10.1016/b978-0-08-100736-5.00013-2 · Cited by 15
Kitagishi, H., Jiromaru, M., & Hasegawa, N. (2020) · ACS Applied Bio Materials · doi:10.1021/acsabm.0c00421 · Cited by 15
HAUSP stabilizes Cdc25A and protects cervical cancer cells from DNA damage response
Das, S., Chandrasekaran, A. P., Jo, K.-S., Ko, N. R., Oh, S. J., Kim, K.-S., & Ramakrishna, S. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2020.118835 · Cited by 16
Self-citationLatest progress in the study of nanoparticle-based delivery of the CRISPR/Cas9 system
Yu, M., Liu, X., Cheng, H., Kuang, L., Zhang, S., & Yan, X. (2021) · Methods · doi:10.1016/j.ymeth.2021.06.004 · Cited by 15
Efficient genome editing in Claviceps purpurea using a CRISPR/Cas9 ribonucleoprotein method
Yu, L., Xiao, M., Zhu, Z., Wang, Y., Zhou, Z., Wang, P., & Zou, G. (2022) · Synthetic and Systems Biotechnology · doi:10.1016/j.synbio.2022.02.002 · Cited by 17
Heinemann, J. A., & Walker, S. (2019) · Biosafety and Health · doi:10.1016/j.bsheal.2019.09.003 · Cited by 15
Skipper, K. A., Nielsen, M. G., Andersen, S., Ryø, L. B., Bak, R. O., & Mikkelsen, J. G. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.02.006 · Cited by 16
Metadata
- Authors
- Ramakrishna, S., Kwaku Dad, A.-B., Beloor, J., Gopalappa, R., Lee, S.-K., & Kim, H.
- Affiliations
- Hanyang University (KR)
- Venue
- Genome Research
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2014-04-02
- Volume
- 24
- Issue
- 6
- Pages
- 1020-1027
- ISSN
- 1088-9051 (ISSN-L)
- PMC
- PMC4032848
- OpenAlex
- W2103609218
- Cited by
- 655
- References
- 45
- Citations by year
- 2026: 16 · 2025: 31 · 2024: 41 · 2023: 46 · 2022: 64 · 2021: 76 · 2020: 66 · 2019: 60 · 2018: 77 · 2017: 60 · 2016: 56 · 2015: 50 · 2014: 11
- Type
- posted content
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- Genome Research (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- National Research Foundation
- Hanyang University
- Yonsei University
- Korea Basic Science Institute
- National Research Foundation of Korea (2013M3A9B4076544, 2011‐0019357)
- Korea Advanced Institute of Science and Technology
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
- Keywords
- CRISPR/Cas9, cell-penetrating peptides, gene disruption, genome editing, guide RNA delivery, off-target mutations, embryonic stem cells, human cell lines
- MeSH terms
- RNA, Guide, CRISPR-Cas Systems, Humans, Transfection, Genome, Human, Mutagenesis, Site-Directed, RNA Editing, RNA, Guide, Kinetoplastida, Cell Line, Tumor, Nanoparticles, HEK293 Cells, Cell-Penetrating Peptides, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
